信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01801 信达生物

已收盘 03-25 16:08:32

82.550

+1.000

+1.23%

最高84.350	最低81.850	成交量848.95万
今开83.600	昨收81.550	日振幅3.07%
总市值1,432亿	流通市值1,432亿	总股本17.35亿
成交额7.04亿	换手率0.49%	流通股本17.35亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":82.55,"timestamp":1774426112003,"preClose":81.55,"halted":0,"volume":8489500,"delay":0,"changeRate":0.012262415695892091,"floatShares":1735000000,"shares":1735000000,"eps":-0.06,"marketStatus":"已收盘","change":1,"latestTime":"03-25 16:08:32","open":83.6,"high":84.35,"low":81.85,"amount":703506233,"amplitude":0.030656,"askPrice":82.55,"askSize":17500,"bidPrice":82.5,"bidSize":12500,"shortable":3,"etf":0,"ttmEps":0.739283,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774488600000},"marketStatusCode":5,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":81.55,"openAndCloseTimeList":[[1774402200000,1774411200000],[1774414800000,1774425600000]],"volumeRatio":0.835146,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.5802,"impliedVolPercentile":0.5244},"requestUrl":"/m/hq/s/01801","defaultTab":"news","newsList":[{"id":"2622001480","title":"信达生物(01801)与礼来制药的战略合作已生效 澄清非收购交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2622001480","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622001480?lang=zh_cn&edition=full","pubTime":"2026-03-25 07:43","pubTimestamp":1774395814,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物(01801)发布公告，关公司于2026年2月8日就与礼来制药签署战略合作协议以推动肿瘤学及免疫学领域新药研发所作出的公告。公司已获联邦贸易委员会提前批准，至此，礼来制药与公司之间战略合作协议生效的所有先决条件均已达成。该战略合作协议已于香港时间2026年3月24日生效。公司注意到，部分媒体报导错误地将该战略合作协议的生效解读为对公司的收购。公司谨此澄清，公司并未，亦无意进行该等交易。谨此提醒股东及有意投资者，切勿依赖有关集团的市场传闻。有关集团的任何资讯，应仅以公司的官方公告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418432.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B4JS1V06.HKD","LU2756315664.SGD","IE00BKPKM429.USD","SGXZ31699556.SGD","BK1583","LU0672654240.SGD","LU1093756168.USD","SG9999013999.USD","LU1551013342.USD","LU2360106947.USD","LU0683600562.USD","LU2168564222.USD","LU2896262040.SGD","LLYX","LU2488822045.USD","SG9999014898.SGD","IE0009355771.USD","LU2237443978.SGD","LU1868836914.USD","LU2602419157.SGD","LU0455707207.USD","LU1814569148.SGD","LU0354030511.USD","LU2168564495.EUR","LU0417517546.SGD","IE00B1XK9C88.USD","LU2023250330.USD","LU2471134952.CNY","IE00BWXC8680.SGD","BK4516","BK1574","LU0708995401.HKD","LLII","LU0823416689.USD","LU1291159041.SGD","BK1161","SG9999015945.SGD","LU1868836757.USD","IE0001KFT4U8.USD","LU1127390331.HKD","LU2552382132.HKD","LU0502904849.HKD","LU2552382215.SGD","IE00B7KXQ091.USD","LU0471298777.SGD","LU1548497426.USD","LU0787776722.HKD","LU2087625088.SGD","LU2456880835.USD","IE00B1BXHZ80.USD","LU2491050154.USD","LU2211815571.USD","LU2213496289.HKD","SGXZ51526630.SGD","LU2106854487.HKD","LU0238689110.USD","IE00B2B36J28.USD","SGXZ57979304.SGD","LU0786609619.USD","SG9999014906.USD","LU1989771016.USD","IE00BJJMRY28.SGD","LU0289739699.SGD","LU0471298694.HKD","LU2264538146.SGD","LU0353189680.USD","LU2357305700.SGD","BK4599","ELIS","SG9999015952.SGD","LU0354030438.USD","LU0432979614.USD","LU2097828474.EUR","LU2471134796.USD","LU1280957306.USD","LU0058720904.USD","LU0203202063.USD","LU2089284900.SGD","LU2089984988.USD","GB00BDT5M118.USD","BK4585","SG9999014880.SGD","LU1093756325.SGD","LU0266013472.USD","LU1267930730.SGD","LU1323610961.USD","LU2491050071.SGD","LU1969619763.USD","LU0640476718.USD","LU0320765059.SGD","IE0005OL40V9.USD","LU2471134879.HKD","LU1023059063.AUD","IE00BJT1NW94.SGD","BK4533","LU0256863811.USD","LU0385154629.USD","LU0882574139.USD","LU1061106388.HKD","LU2328871848.SGD","SG9999015986.USD","IE00BJLML261.HKD","LU1804176565.USD","LU0225283273.USD","LU2237438978.USD","LU2237443382.USD","BK4588","LU0964807845.USD","LU1988902786.USD","LU2361044865.SGD","LU2471134523.USD","SG9999001176.SGD","LU2168564065.EUR","LU1232071149.USD","IE00BJJMRZ35.SGD","LU0096364046.USD","LU0889565916.HKD","LU0234572021.USD","LU1366192091.USD","IE00B4R5TH58.HKD","LU0353189763.USD","LU2089283258.USD","LU1145028129.USD","LU2746668974.SGD","SG9999018857.SGD","LU0097036916.USD","LLYZ","LU2237443549.SGD","BK1191","01801","LU2271345857.HKD","LU2168564149.EUR","SGXZ99366536.SGD","LU1917777945.USD","LU0061475181.USD","LU1868837136.USD","LU2097828631.EUR","LU1035775433.USD","IE00BK4W5L77.USD","LU0256863902.USD","LU2417539215.USD","LU0114720955.EUR","LU2552382058.USD","IE00BFSS7M15.SGD","LU0820561909.HKD","BK4534","LU2324357040.USD","ELIL","LU2168563687.JPY","LU0122379950.USD","LU1868836591.USD","LU2468319806.SGD","IE00BK4W5M84.HKD","LU2097828557.USD","LU1069344957.HKD","LU2461242641.AUD","LU2097828714.EUR","LU0106261372.USD","LU2111349929.HKD","LU0109391861.USD","IE00BFSS8Q28.SGD","LU1623119135.USD","LU0320765992.SGD","LU2265009873.SGD","SG9999001176.USD","LU0158827948.USD","LU2023250504.SGD","LU0203201768.USD","LU1057294990.SGD","LU2746668461.USD","LU0689472784.USD","IE0004445015.USD","IE0004445239.USD","LU2491049909.HKD","LU0210536198.USD","LU2756315318.SGD","BK4581","BK1589","LU2108987350.USD","LU2237443895.HKD","SG9999014914.USD","LU1064131342.USD","LU1868837300.USD","LU1983299246.USD","LU2237443465.HKD","IE00BKDWB100.SGD","LU0109394709.USD","IE0002141913.USD","SG9999017495.SGD","LU2462157665.USD","IE00B775H168.HKD","LU0456855351.SGD","LU2236285917.USD","LU1720051017.SGD","LU2361044949.HKD","LU2750360641.GBP","LU2028103732.USD","LU0820562030.AUD","LU1712237335.SGD","LU0316494557.USD","LU1720051108.HKD","LU0158827781.USD","BK4007","LU0823434583.USD","LU2023251221.USD","SG9999018865.SGD","LU1974910355.USD","LU2361045086.USD","LU0323591593.USD","LU2242644610.SGD","LU1551013425.SGD","IE00BJJMRX11.SGD","IE00BFTCPJ56.SGD","LU2097828805.USD","SG9999015978.USD","LU0823434740.USD","LU0882574055.USD","LU2750360997.AUD","LU0006306889.USD","LU1629891620.HKD","LU0094547139.USD","LU0466842654.USD","LU0943347566.SGD","LU0820561818.USD","LU0079474960.USD","LU2063271972.USD","SGXZ81514606.USD","LU0198837287.USD","HK0000165453.HKD","IE00BN29S564.USD","LU2237443622.USD","LU2112291526.USD"],"gpt_icon":0},{"id":"1171306437","title":"信达生物与礼来战略合作协议生效先决条件已全部满足","url":"https://stock-news.laohu8.com/highlight/detail?id=1171306437","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171306437?lang=zh_cn&edition=full","pubTime":"2026-03-25 07:02","pubTimestamp":1774393332,"startTime":"0","endTime":"0","summary":"信达生物与礼来公司达成的战略合作协议，其生效所需满足的全部先决条件现已完成。\n此举标志着双方在生物医药领域的合作迈入了全新的实质性阶段，为后续的深度协作奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0455707207.USD","LU2328871848.SGD","01801","LU1969619763.USD","BK1583","LU2097828805.USD","HK0000165453.HKD","BK1589","LU0502904849.HKD","LU2097828631.EUR","LU2097828714.EUR","LU2242644610.SGD","LU2488822045.USD","LU2097828474.EUR","LU2097828557.USD"],"gpt_icon":0},{"id":"2621069604","title":"摩根大通增持信达生物(01801)约49.78万股 每股作价约82.28港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621069604","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621069604?lang=zh_cn&edition=full","pubTime":"2026-03-24 19:02","pubTimestamp":1774350158,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，3月19日，摩根大通增持信达生物(01801)49.7823万股，每股作价82.2756港元，总金额约为4095.87万港元。增持后最新持股数目约为8724.97万股，持股比例为5.02%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418148.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"摩根大通增持信达生物(01801)约49.78万股 每股作价约82.28港元","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064131342.USD","LU0683600562.USD","LU0265550359.USD","LU0345770993.USD","LU0265550946.USD","LU2097828474.EUR","LU0455707207.USD","LU0976567544.SGD","IE00BJLML261.HKD","BK4585","IE00BWXC8680.SGD","LU1496350171.SGD","IE00B3S45H60.SGD","BK1589","LU1496350502.SGD","LU0070302665.USD","LU2430703251.USD","JPMO","BK4588","LU1551013425.SGD","LU2328871848.SGD","BK4566","LU0942090050.USD","LU0943347566.SGD","LU0208291251.USD","LU2106854487.HKD","BK1161","LU2097828557.USD","LU1244550577.SGD","LU2237443622.USD","LU1261432733.SGD","LU1280957306.USD","01801","LU0417517546.SGD","LU1988902786.USD","IE000M9KFDE8.USD","LU1116320737.USD","LU0215105999.USD","BK4581","LU1244550221.USD","BK4207","LU2097828805.USD","IE00BLSP4452.SGD","LU1670627923.USD","LU2211815571.USD","LU1119994496.HKD","LU0345769128.USD","LU0006306889.USD","LU0964807845.USD","LU0640476718.USD"],"gpt_icon":0},{"id":"1150862394","title":"信达生物Efdamrofusp Alfa（IBI302）III期注册STAR研究达主要终点，成中国首个自主研发的NAMD长效疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1150862394","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150862394?lang=zh_cn&edition=full","pubTime":"2026-03-24 08:03","pubTimestamp":1774310593,"startTime":"0","endTime":"0","summary":"信达生物制药宣布，其自主研发的Efdamrofusp Alfa（研发代号：IBI302）用于治疗新生血管性年龄相关性黄斑变性（nAMD）的III期注册临床研究（STAR研究）已达到主要研究终点。该成果标志着IBI302有望成为中国首个本土研发的延长给药间隔的nAMD治疗药物，为患者提供更便捷的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828557.USD","HK0000165453.HKD","LU0455707207.USD","BK1589","BK1583","LU0502904849.HKD","LU2097828805.USD","LU2097828714.EUR","LU2328871848.SGD","LU2097828474.EUR","LU2488822045.USD","01801","BK1161","LU2097828631.EUR","LU1969619763.USD","LU2242644610.SGD"],"gpt_icon":0},{"id":"2620449806","title":"招银国际：料中国医疗行业基本面加速向好 推荐买信达生物(01801)三生制药(01530)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2620449806","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620449806?lang=zh_cn&edition=full","pubTime":"2026-03-17 15:07","pubTimestamp":1773731228,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，MSCI中国医疗指数2026年初至今累计上涨0.6%，跑赢MSCI中国指数3.5%。医药行业近期明显回调，特别是创新药板块回调幅度较大。同时，AI制药技术突破与中国创新药踏出海外BD的爆发形成双重共振，该行预计行业基本面加速向好。该行表示，推荐买入信达生物、三生制药、加科思、固生堂 、药明合联，目标价分别110.62港元、37.43港元、10.34港元、44.95港元及88港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d0f3c5bccb622a532fbc5668691928ff","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414821.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2328871848.SGD","HK0000165453.HKD","LU2097828631.EUR","01530","BK1141","LU2242644610.SGD","BK1574","LU1969619763.USD","01801","LU0502904849.HKD","BK1219","SG9999014674.SGD","LU2097828805.USD","LU2097828557.USD","159891","01167","02268","LU2097828714.EUR","LU0455707207.USD","BK1593","BK1583","LU2097828474.EUR","BK1161","BK1589","LU2488822045.USD","02273"],"gpt_icon":0},{"id":"2618925435","title":"医药生物行业周报：罗伐昔替尼达成高额独家授权协议，创新药BD交易持续活跃","url":"https://stock-news.laohu8.com/highlight/detail?id=2618925435","media":"上海证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618925435?lang=zh_cn&edition=full","pubTime":"2026-03-11 14:05","pubTimestamp":1773209138,"startTime":"0","endTime":"0","summary":"主要观点2026年3月4日，中国生物制药宣布与赛诺菲就罗伐昔替尼达成独家授权协议。根据协议，中国生物制药子公司正大天晴授予赛诺菲在全球范围内开发、生产及商业化罗伐昔替尼的独家许可。四起交易均为临床前资产，彰显中国源头创新能力获全球认可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031114054897ad2986&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031114054897ad2986&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1226287529.USD","HK0000165453.HKD","LU0326950275.SGD","LU1960683339.HKD","BK1521","BK1574","IE0008369823.USD","LU1807302812.USD","LU0067412154.USD","BK1515","LU1226288170.HKD","IE00BZ08YS42.EUR","LU0315179316.USD","LU1226287792.SGD","SG9999004220.SGD","BK1191","LU1993786604.SGD","LU0072913022.USD","LU0314109678.HKD","LU0140636845.USD","LU1328277881.USD","IE00B543WZ88.USD","LU1152091168.USD","LU0501845795.SGD","LU1951186391.HKD","IE0008368742.USD","LU1226288253.USD","LU0880133367.SGD","LU1226287875.USD","IE00B5MMRT66.SGD","IE00B031HY20.USD","01177","LU1813983027.USD","LU2039709279.SGD","01801","LU1008478684.HKD","BK1161","IE00BZ08YT58.USD","LU1152091754.HKD","IE00BZ08YR35.GBP","01093","06978"],"gpt_icon":0},{"id":"2618094075","title":"翰森制药、恒瑞医药等齐发力，国产GLP-1类减重药加速“破圈”","url":"https://stock-news.laohu8.com/highlight/detail?id=2618094075","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618094075?lang=zh_cn&edition=full","pubTime":"2026-03-11 11:32","pubTimestamp":1773199961,"startTime":"0","endTime":"0","summary":"据悉，在减重药物领域，GLP-1类药物成为热门赛道，国内一批药企也积极抢占这一赛道，并逐渐迎来收获。除了翰森制药外，还有一批国产GLP-1类新药正在加速推进临床。值得一提的是，目前已有多个国产GLP-1类新药获批上市。从临床推进到上市落地，国产GLP-1类药物的多点突破，彰显了我国生物医药产业的自主创新实力。未来，随着药企持续加大研发投入，聚焦剂型创新、适应症拓展，国产GLP-1类药物将在全球肥胖防控领域发挥更重要的作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031111372197acfd6f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031111372197acfd6f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201885.HKD","LU1023057109.AUD","BK1191","01801","LU0359202008.SGD","LU2543165471.USD","03692","BK1589","01276","BK1583","LU0359201612.USD"],"gpt_icon":0},{"id":"2618629569","title":"每日卖空追踪 | 信达生物 03月10日卖空量成交156.45万股，卖空比例为12.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618629569","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618629569?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:30","pubTimestamp":1773131425,"startTime":"0","endTime":"0","summary":"信达生物北京时间03月10日，涨4.95%，卖空量成交156.45万股，较上一交易日减少63.74%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310163303a45df73a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310163303a45df73a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828714.EUR","LU2328871848.SGD","01801","LU2242644610.SGD","LU0455707207.USD","LU2097828805.USD","LU0502904849.HKD","LU2097828474.EUR","BK1583","HK0000165453.HKD","LU1969619763.USD","LU2097828557.USD","LU2488822045.USD","LU2097828631.EUR","BK1589","BK1161"],"gpt_icon":0},{"id":"2618896295","title":"信达生物03月10日主力净流入3770.6万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2618896295","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618896295?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:16","pubTimestamp":1773130560,"startTime":"0","endTime":"0","summary":"03月10日, 信达生物股价涨4.95%，报收85.80元，成交金额10.9亿元，换手率0.73%，振幅3.30%，量比0.89。信达生物今日主力资金净流入3770.6万元，上一交易日主力净流出3281.8万元。该股近5个交易日上涨8.00%，主力资金累计净流入2996.7万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入3.6亿元，其中净流入天数为17日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310162128a45dec7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310162128a45dec7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828474.EUR","BK1161","LU2097828714.EUR","BK1583","LU0455707207.USD","LU1969619763.USD","LU0502904849.HKD","01801","LU2328871848.SGD","BK1589","LU2242644610.SGD","LU2097828557.USD","LU2097828631.EUR","LU2488822045.USD","HK0000165453.HKD","LU2097828805.USD"],"gpt_icon":0},{"id":"2618360608","title":"信达生物IBI3033启动一期临床 适应症为哮喘、特应性皮炎","url":"https://stock-news.laohu8.com/highlight/detail?id=2618360608","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618360608?lang=zh_cn&edition=full","pubTime":"2026-03-09 18:03","pubTimestamp":1773050580,"startTime":"0","endTime":"0","summary":"药物临床试验登记与信息公示平台数据显示，信达生物制药（苏州）有限公司的IBI3033在健康受试者中安全性、耐受性及药代动力学的随机、双盲、安慰剂对照的多次给药研究已启动。本次试验主要目的为评估健康受试者接受IBI3033多次给药后的安全性和耐受性。IBI3033为生物制品，适应症为哮喘、特应性皮炎。哮喘是气道慢性炎症性疾病，表现为喘息、气促等；特应性皮炎是慢性复发性炎症性皮肤病，以剧烈瘙痒和湿疹样皮疹为特征。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030919044097ab0b06&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030919044097ab0b06&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0502904849.HKD","LU2328871848.SGD","LU2097828714.EUR","LU0455707207.USD","LU2097828805.USD","LU2097828557.USD","BK1583","HK0000165453.HKD","LU2097828631.EUR","LU2097828474.EUR","BK1161","LU2242644610.SGD","BK1589","LU1969619763.USD","LU2488822045.USD","01801"],"gpt_icon":0},{"id":"2618608345","title":"信达生物03月09日主力净流出3281.8万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2618608345","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618608345?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:15","pubTimestamp":1773044136,"startTime":"0","endTime":"0","summary":"03月09日, 信达生物股价跌1.86%，报收81.75元，成交金额14.6亿元，换手率1.05%，振幅5.76%，量比1.44。信达生物今日主力资金净流出3281.8万元，上一交易日主力净流入557.0万元。该股近5个交易日下跌0.24%，主力资金累计净流入1092.3万元；近20日主力资金累计净流入3.3亿元，其中净流入天数为17日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309161751a6b1b549&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309161751a6b1b549&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801","BK1589","LU0502904849.HKD","LU0455707207.USD","LU2097828474.EUR","LU2097828805.USD","LU2242644610.SGD","BK1583","LU2488822045.USD","HK0000165453.HKD","LU2097828714.EUR","LU2097828557.USD","LU1969619763.USD","LU2097828631.EUR","LU2328871848.SGD","BK1161"],"gpt_icon":0},{"id":"2617635561","title":"顶尖药企竞相推出减重口服药","url":"https://stock-news.laohu8.com/highlight/detail?id=2617635561","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617635561?lang=zh_cn&edition=full","pubTime":"2026-03-06 22:16","pubTimestamp":1772806560,"startTime":"0","endTime":"0","summary":"全球减重药物市场正进入新阶段，推动因素包括口服剂型上市、仿制药竞品即将到来，以及礼来、诺和诺德旗下重磅产品在美国降价。　　这一快速变化的格局，促使华尔街重新审视未来十年减重药市场规模将达 1500 亿美元的长期预测。　　诺和诺德成为首家推出口服 GLP1 减重药的企业，这家丹麦药企在快速演变的减重治疗市场中获得了竞争优势。　　中国歌礼制药的在研口服 GLP1 药物ASC30，在美国二期临床试验中最高减重7.7%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-06/doc-inhqanka2342553.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000165453.HKD","SG9999002232.USD","SG9999001176.USD","BK4588","IE00BLSP4239.USD","LU0225284248.USD","SG9999013999.USD","BK1583","AZN","BK4581","LU1894683348.USD","LU2097828714.EUR","SG9999003800.SGD","LU0225771236.USD","LU1066053197.SGD","LU2097828557.USD","000963","LU2097828631.EUR","LU1057294990.SGD","LU1883839398.USD","LU0170899867.USD","LU2328871848.SGD","MRK","BK4533","LU0306806265.USD","LU2488822045.USD","SG9999001176.SGD","VKTX","SG9999011175.SGD","LU0321505439.SGD","LU0058720904.USD","PFE","LU0122379950.USD","LU1023059063.AUD","IE00BBT3K403.USD","BK4007","LLY","LU1066051498.USD","IE0002270589.USD","LU2097828474.EUR","IE000M9KFDE8.USD","LU2097828805.USD","BK4534","LU0234572021.USD","LU2242644610.SGD","RHHBY","LU0502904849.HKD","BK4550","SGXZ57979304.SGD","LU1969619763.USD","BK4585","LU0321505868.SGD","LU0456855351.SGD","IE00BLSP4452.SGD","01801","LU0306807586.USD","SG9999002224.SGD","BK4592","BK1161","LU0455707207.USD","LU0289739699.SGD","LU1894683264.USD","BK4568","LU0985481810.HKD","LU0868494617.USD","IE00B19Z3B42.SGD","BK1589","BK4599","IE00B19Z3581.USD","NVO"],"gpt_icon":1},{"id":"2617656650","title":"每日卖空追踪 | 信达生物 03月06日卖空量成交119.5万股，卖空比例为9.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617656650","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617656650?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:30","pubTimestamp":1772785824,"startTime":"0","endTime":"0","summary":"信达生物北京时间03月06日，涨6.18%，卖空量成交119.5万股，较上一交易日减少53.49%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306163300a6aa3c7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306163300a6aa3c7b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828557.USD","HK0000165453.HKD","LU0455707207.USD","BK1589","BK1583","LU0502904849.HKD","LU2097828805.USD","LU2097828714.EUR","LU2328871848.SGD","LU2097828474.EUR","LU2488822045.USD","01801","BK1161","LU2097828631.EUR","LU1969619763.USD","LU2242644610.SGD"],"gpt_icon":0},{"id":"2617504034","title":"15亿美元再添捷报！2026国产创新药出海热潮仍在持续","url":"https://stock-news.laohu8.com/highlight/detail?id=2617504034","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617504034?lang=zh_cn&edition=full","pubTime":"2026-03-06 09:42","pubTimestamp":1772761338,"startTime":"0","endTime":"0","summary":"春节过后，国产创新药出海热潮丝毫不减，持续书写着中国医药创新的全球化新篇章。进入3月份，创新药出海又传来捷报，中国生物制药宣布达成15.3 亿美金创新药授权交易。据悉，2026年开年至今，中国药企出海节奏密集。如信达生物与礼来制药再次达成战略合作，合作金额最高达88.5亿美元，双方将在肿瘤和免疫疾病领域联合开发全新药物。协议未披露涉及的具体药物数量。展望2026年，国产创新药出海将呈现出全新格局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306094344a451ed8b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306094344a451ed8b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01177","IE00BZ08YS42.EUR","BK1515","BK1191","BK1521","01801","IE00BZ08YT58.USD","06978","BK1589","IE00BZ08YR35.GBP","HK0000165453.HKD","BK1574"],"gpt_icon":0},{"id":"2617465660","title":"信达生物盘中异动 快速上涨3.00%报80.800港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617465660","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617465660?lang=zh_cn&edition=full","pubTime":"2026-03-06 09:36","pubTimestamp":1772761004,"startTime":"0","endTime":"0","summary":"2026年03月06日早盘09时36分，信达生物股票出现波动，股价快速上涨3.00%。截至发稿，该股报80.800港元/股，成交量61.54万股，换手率0.04%，振幅3.31%。资金方面，该股资金流入2202.08万港元，流出1472.84万港元。信达生物股票所在的药品行业中，整体涨幅为0.18%。其相关个股中，劲方医药-B、和黄医药、恒瑞医药涨幅较大，振幅较大的相关个股有和黄医药、德琪医药-B、长风药业，振幅分别为5.70%、5.18%、4.60%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306093644954339a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306093644954339a6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828474.EUR","BK1161","LU2242644610.SGD","01801","LU2328871848.SGD","BK1589","LU2097828557.USD","LU2097828631.EUR","LU2097828714.EUR","LU2097828805.USD","LU0455707207.USD","HK0000165453.HKD","LU2488822045.USD","BK1583","LU0502904849.HKD","LU1969619763.USD"],"gpt_icon":0},{"id":"2617500116","title":"信达生物制药2026年2月股份变动月报","url":"https://stock-news.laohu8.com/highlight/detail?id=2617500116","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617500116?lang=zh_cn&edition=full","pubTime":"2026-03-05 22:13","pubTimestamp":1772720026,"startTime":"0","endTime":"0","summary":"金吾财讯|信达生物制药于2026年3月5日提交了2026年2月的股份变动月报表。在股份期权方面，公司的首次公开发售前股份奖励计划、首次公开发售后雇员持股计划以及2024年股份计划均未有新的股份发行或库存股份转让。同时，公司在该月内也未进行任何股份回购、股权激励计划的行权或其他导致已发行股份或库存股份变动的操作。综上所述，信达生物制药在2026年2月的股份结构保持稳定，未发生任何变动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305222756a4503acf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305222756a4503acf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0502904849.HKD","LU2097828805.USD","LU2242644610.SGD","LU2097828631.EUR","LU0455707207.USD","BK1583","LU2097828474.EUR","BK1191","BK1589","HK0000165453.HKD","LU2097828557.USD","LU2328871848.SGD","01801","BK1574","01477","LU1969619763.USD","LU2097828714.EUR","LU2488822045.USD","BK1161"],"gpt_icon":0},{"id":"1152462988","title":"信达生物（01801）2月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1152462988","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152462988?lang=zh_cn&edition=full","pubTime":"2026-03-05 20:36","pubTimestamp":1772714179,"startTime":"0","endTime":"0","summary":"信达生物制药（01801）于2026年3月5日披露截至2026年2月28日的股份变动月报表。报告显示，公司法定注册股本维持在5,000,000,000股（面值USD 0.00001），注册股本总额为USD 50,000。已发行股份数量为1,735,186,039股，与上月底相同，未见新增发行或回购、注销及库藏股变动。\n期权与激励计划方面，首发前股份奖励计划、首发后员工持股计划及2024年股份计划在报告期内均无行使或新增发行。部分期权被注销24,750股，但并未导致公司已发行股份总数发生变化。公司表示，将继续遵守香港联合交易所有限公司《上市规则》及相关法律法规。此次月报由公司联席公司秘书签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"gpt_icon":0},{"id":"2617278545","title":"摩根大通增持信达生物(01801)约40.86万股 每股作价约84.94港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617278545","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617278545?lang=zh_cn&edition=full","pubTime":"2026-03-05 18:58","pubTimestamp":1772708286,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，2月27日，摩根大通增持信达生物(01801)40.863万股，每股作价84.9352港元，总金额约为3470.71万港元。增持后最新持股数目约为8690.81万股，最新持股比例为5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2456880835.USD","LU0971096721.USD","LU1366192091.USD","LU0149725797.USD","LU2237443549.SGD","LU0211331839.USD","LU1969619763.USD","LU2505996509.AUD","BK1583","IE00B1BXHZ80.USD","LU2462157665.USD","IE00BJLML261.HKD","LU1116320901.HKD","LU2023250504.SGD","JPMO","LU0496365809.HKD","LU0640476718.USD","LU1720051017.SGD","LU2430703095.HKD","HK0000165453.HKD","LU2430703251.USD","LU1894683264.USD","IE00B1XK9C88.USD","01801","IE00BZ1G4Q59.USD","LU0964807845.USD","LU2097828714.EUR","LU1551013425.SGD","LU0208291251.USD","LU2746668461.USD","IE00BKDWB100.SGD","BK4581","LU1145028129.USD","LU1974910355.USD","BK1161","LU1988902786.USD","LU2237443895.HKD","LU0170899867.USD","BK1589","LU0203345920.USD","LU0882574139.USD","LU2242644610.SGD","LU1084165304.USD","LU0345770308.USD","LU1032466523.USD","LU0787776722.HKD","LU1668664300.SGD","LU2106854487.HKD","LU2552382058.USD","LU0868494708.USD"],"gpt_icon":0},{"id":"2617974593","title":"每日卖空追踪 | 信达生物 03月04日卖空量成交205.5万股，卖空比例为11.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617974593","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617974593?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:30","pubTimestamp":1772613024,"startTime":"0","endTime":"0","summary":"信达生物北京时间03月04日，跌3.06%，卖空量成交205.5万股，较上一交易日减少14.99%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304163300a44a6c30&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304163300a44a6c30&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0502904849.HKD","01801","LU2097828557.USD","BK1161","LU2097828805.USD","LU2242644610.SGD","LU2097828714.EUR","LU2488822045.USD","HK0000165453.HKD","LU0455707207.USD","BK1583","LU2097828474.EUR","BK1589","LU2097828631.EUR","LU1969619763.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2616565307","title":"大摩：中国生科板块催化剂集中下半年 重新覆盖信达生物(01801)予“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2616565307","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616565307?lang=zh_cn&edition=full","pubTime":"2026-03-04 11:02","pubTimestamp":1772593364,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根士丹利发布研报称，重新覆盖信达生物，并予“增持”评级，目标价130港元。报告指，中国生物科技板块今年进入转折期，基本面正在稳定，创新基础具韧性，授权交易正在进行，融资活动持续复苏。大摩料中国生物科技板块上半年将区间波动; 而催化剂、资金重新配置及更理想估值，将在今年下半年更明确的股价方向奠定基础。大摩预期中国生物科技板块今年上半年区间波动、下半年方向趋向明确。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409816.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01801"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":-0.0292},{"period":"1month","weight":-0.1014},{"period":"3month","weight":0.0099},{"period":"6month","weight":-0.142},{"period":"1year","weight":1.0211},{"period":"ytd","weight":0.0695}],"compareEarnings":[{"period":"1week","weight":-0.0311},{"period":"1month","weight":-0.0511},{"period":"3month","weight":-0.0293},{"period":"6month","weight":-0.0537},{"period":"1year","weight":0.0484},{"period":"ytd","weight":-0.0221}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"信达生物制药是一家主要从事研发、生产及销售治疗肿瘤、心血管及代谢（CVM）、自身免疫及眼科等重大疾病创新药物的投资控股公司。药物形式包括单克隆抗体、多特异性抗体、免疫细胞因子、抗体偶联药物（ADC）、细胞治疗及小分子药物等。该公司的主要产品包括达伯舒（信迪利单抗注射液）、达攸同（贝伐珠单抗注射液）、苏立信（阿达木单抗注射液）、达伯华（利妥昔单抗注射液）、达伯坦（佩米替尼片）等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.041076},{"month":2,"riseRate":0.75,"avgChangeRate":0.110526},{"month":3,"riseRate":0.25,"avgChangeRate":-0.024261},{"month":4,"riseRate":0.714286,"avgChangeRate":0.040816},{"month":5,"riseRate":0.428571,"avgChangeRate":0.027398},{"month":6,"riseRate":0.714286,"avgChangeRate":0.139165},{"month":7,"riseRate":0.428571,"avgChangeRate":0.010056},{"month":8,"riseRate":0.714286,"avgChangeRate":0.000214},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032182},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.02286},{"month":11,"riseRate":0.625,"avgChangeRate":0.079172},{"month":12,"riseRate":0.375,"avgChangeRate":0.024026}],"exchange":"SEHK","name":"信达生物","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}